Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics. Alex: It’s complicated. We, for very complicated reasons, ended up with niacin.
91 
Let's personalize your content